Anavex Life Sciences Corp (AVXL)

[RedShoulder]

AVXL vs SAVA and ANVS

1) SAVA is being sued, and apparently for good reasons.

2) SAVA's trial data has been shown to be manipulated.

3) SAVA is at least two years behind AVXL if not more for AD and SAVA is still in the recruitment stage; while AVXL is in a potentially pivotal Ph-2b/3 trial in current progress which will conclude in May.

4) AVXL extensive and deep pipeline with 11 trials listed in various stages and 6 in pre clinical. Sava has just AD.

5) A2-73 works upstream eliminating the need for SAVA's downstream drug, making it redundant and not needed.

6) AVXL has a review paper in 'Scientific Reports' a publication by 'Nature', SAVA's paper was rejected, probably because of the bogus trial data.

7) AVXL has 4 drugs that will be used in various trials, SAVA has only 1 drug.

8) AVXL's A2-73 Blarcamesine will be approved and marketed with huge revenues, while SAVA is still in trials.

ANVS is so far behind, more than 3 years on AD if not more, that I'm not going to bother laying out the case against them. AVXL will have A2-73 Blarcamesine approved and earning revenues while they will still be years behind. No competition at all.

Another day underperforming the sector

AVXL + 3.14%
SAVA + 9.53%
ANVS + 7.11%

Meanwhile while we wait for news, the only thing blanketing the news wire for the other 2 companies is Class Action Update and Shareholder Alerts from law firms. Yet we continue to underperform.

Simonizer, as you can see by the comparisons above, it is totally bewildering that SAVA has a larger Market Cap. It does not make any common sense if just a little Due Diligence is applied to both companies. SMH